IL17A and psoriasis: Our multi-omics approach provides novel translational evidence in human psoriasis skin that systemic anti-IL-17A monoclonal antibody administration not only blocks the entire feed-forward inflammatory amplification loop between T-cells, DCs, and KCs, but also promotes regulatory transcriptome modification in regulatory DCs.